US SEC Trading Suspension Halt Orders — April 03, 2026

03-04-2026

On March 31, 2026, Aeries Technology, Inc. received formal notice from Nasdaq's Listing Qualifications Staff that its failure to comply with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) will result in delisting of its Class A ordinary shares (AERT) and redeemable warrants (AERTW) unless the company requests a hearing. The company intends to timely request a hearing before the Nasdaq Hearings Panel, which will stay delisting pending the panel's decision and any potential extension. This follows an initial deficiency notice on September 30, 2025, with the grace period expiring on March 30, 2026, and no eligibility for a second grace period due to unmet stockholders’ equity requirements.

• ·Company address: 60 Paya Lebar Road, #08-13 Paya Lebar Square, Singapore 409051
• ·Telephone: (919) 228-6404
• ·Commission File Number: 001-40920
• ·IRS Employer Identification No.: 98-1587626
• ·Nasdaq trading symbols: AERT (Class A ordinary shares), AERTW (redeemable warrants)

03-04-2026

Twin Vee PowerCats Co. received a notification letter from Nasdaq on April 2, 2026, stating it no longer meets the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2), based on closing bid prices below $1.00 for 30 consecutive business days from February 18, 2026, to March 31, 2026. Due to a prior 1-for-10 reverse stock split on April 7, 2025, the company is ineligible for a 180-calendar-day compliance period under Nasdaq Listing Rule 5810(c)(3)(A). The company plans to request a hearing by April 9, 2026, to appeal, which would stay delisting pending the Panel's decision, though success is not assured.

• ·Deficiency period: 30 consecutive business days from February 18, 2026, to March 31, 2026
• ·Previous reverse stock split: 1-for-10 effective April 7, 2025
• ·Hearing request deadline: April 9, 2026
• ·Applicable rules: Nasdaq Listing Rule 5550(a)(2) and 5810(c)(3)(A)

03-04-2026

Matinas BioPharma Holdings, Inc. received a notice from NYSE American on April 2, 2026, for failing to meet continued listing standards under Sections 1003(a)(i), (ii), and (iii) due to stockholders’ equity of $4.83 million as of December 31, 2025—below the required $2.0M, $4.0M, and $6.0M thresholds amid losses in its five most recent fiscal years. The company plans to submit a compliance plan by May 2, 2026, potentially gaining up to 18 months to cure the deficiency, with no immediate effect on its NYSE American listing or operations. However, compliance is not assured, and rejection of the plan could lead to delisting proceedings.

• ·Company not currently eligible for any exemption under Section 1003(a) of the NYSE American Company Guide.
• ·Shares of common stock (MTNB) continue to be listed and traded on NYSE American pending compliance with other listing requirements.

03-04-2026

Arrive AI Inc. received two notification letters from Nasdaq on March 31, 2026, for failing to comply with the minimum Market Value of Publicly Held Shares (MVPHS) requirement of $15,000,000 (Nasdaq Listing Rule 5450(b)(2)(C)) and the minimum Market Value of Listed Securities (MVLS) requirement of $50,000,000 (Nasdaq Listing Rule 5450(b)(2)(A)), each for 30 consecutive business days. The Company has 180 calendar days until September 28, 2026, to regain compliance by meeting the respective thresholds for at least 10 consecutive business days, with no immediate impact on trading of its Common Stock (symbol: ARAI) on Nasdaq. Non-compliance may result in delisting or a potential transfer to the Nasdaq Capital Market.

• ·MVPHS non-compliance period: February 11, 2026 to March 31, 2026 (30 consecutive business days).
• ·MVLS non-compliance period: February 10, 2026 to March 30, 2026 (30 consecutive business days).
• ·Common Stock par value: $0.0002 per share.
• ·Commission File Number: 001-42645.
• ·Company is an emerging growth company.

03-04-2026

AEON Biopharma, Inc. received a notice from NYSE American on March 31, 2026, indicating non-compliance with Section 1003(a)(ii) of the Company Guide due to a stockholders' equity deficit of approximately $55 million as of December 31, 2025, and net losses in three of its four most recent fiscal years. This follows a prior notice under Section 1003(a)(i) for insufficient equity of $2.0 million, but the company has an accepted compliance plan extending to August 3, 2026, with its Class A Common Stock continuing to trade on NYSE American under a '.BC' indicator and no immediate delisting effect. While the company reports progress on the plan, it provides no assurance of regaining compliance by the deadline.

• ·Prior non-compliance notice received February 7, 2025, under Section 1003(a)(i).
• ·Annual Report on Form 10-K for year ended December 31, 2025, filed March 30, 2026.
• ·Compliance plan period ends August 3, 2026.
• ·Company has right to appeal delisting determination under Section 1010 and Part 12 of Company Guide.